Diabetes Risk
Conditions
Keywords
Obesity, Adipose tissue inflammation, Salsalate, Hispanics
Brief summary
Background: The prevalence of obesity has increased throughout the last three decades due to genetic, metabolic, behavioral, and environmental factors. Obesity and high-fat western diets activate inflammatory processes, which promote development of insulin resistance as well as other metabolic complications. Increasing obesity rates are a major public health concern in the Hispanic population due to the large number of Hispanics suffering from obesity. Based on preliminary data, we propose a double-blind randomized clinical trial of Salsalate therapy in obese Hispanic young adults. Salsalate treatment shows promise for decreasing inflammation under conditions of weight stability by reducing macrophage infiltration of adipocytes. Hispanics have the greatest amount of visceral adipose tissue (VAT), liver fat, and inflammation when compared to other ethnic groups, thereby increasing the potential for treatment effects in this high-risk population. Purpose: The purpose of this study is to demonstrate through a proof-of-concept trial that Salsalate induced reductions in adipose tissue inflammation are possible under conditions of weight stability. Methodology: We will recruit obese Hispanic young adults (18 - 35 years) from hospitals, clinics, and community centers. Study Endpoints: Primary outcomes will be macrophage infiltration as assessed by the presence of crown-like structures (CLS) in subcutaneous adipose tissue (SAT) biopsies, liver fat, insulin sensitivity, and fasting glucose. We will also assess plasma levels of monocyte chemoattractant protein (MCP)-1, tumor necrosis factor (TNF)-α, interleukin (IL)-1, C-reactive protein (CRP), and SAT gene expression of nuclear factor kB (NF-kB) and insulin signaling pathways. Intervention and Follow-up: Participants will be randomly assigned to four weeks of treatment with Salsalate (4 g/d) or placebo and will be studied under weight maintenance conditions. These measures will enable us to determine if Salsalate treatment is capable of reducing adipose tissue inflammation and related metabolic outcomes in the absence of weight loss.
Interventions
DRUGSalsalate (4 g/day)
Given orally twice daily
DRUGPlacebo (4 g/day)
Given orally twice daily
Sponsors
University of Southern California
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Obese (body mass index \>30 kg/m\^2) * Hispanic males and females age 18-35 years
Exclusion criteria
* Women with hemoglobin \<11.5 g/dL or men with hemoglobin \<12.5 g/dL will be excluded * AST / ALT \>2 times the upper limit of normal * Evidence of any liver disease other than non-alcoholic steatosis * Diabetes * Diagnosis of any disease that is known to influence insulin action and secretion * Current or past involvement in any weight loss, exercise, or sports program in the six months prior to participation * Use of medication known to influence body composition or fat distribution (e.g. Cushing syndrome) * History of renal disease * Use of non-steroidal anti-inflammatory drugs (NSAIDs) * Chicken pox, flu, or influenza infection * Those taking high doses of vitamin C, antacids (containing Ca2+ or Mg+2), or taking Warfarin * Hypertension * Allergies to Salsalate, aspirin or other NSAIDs * History of peptic ulcer or upper GI bleeding * A positive pregnancy test or current lactation * Has smoked greater than 100 cigarettes in their lifetime and now smokes everyday or some days * Drinks greater than 200 g/day of alcohol * Those with a waist circumference (or widest part of body measurement) greater than or equal to 185 cm due to MRI size restrictions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in plasma C-peptide levels over a 2-hour oral glucose tolerance test | 4 weeks | C-peptide following 4 weeks of treatment with salsalate (4 g/day) or placebo. A 2-hour oral glucose tolerance test will be performed at baseline and 4 weeks to measure changes in plasma C-peptide levels. |
| Change in adipose tissue inflammation | 4 weeks | Adipose tissue inflammation following 4 weeks of treatment with salsalate (4 g/day) or placebo. Adipose tissue inflammation will be determined from abdominal subcutaneous adipose tissue biopsies performed at baseline and 4 weeks. |
| Change in systemic markers of inflammation | 4 weeks | Systemic markers of inflammation following treatment with salsalate (4 g/day) or placebo. Fasting blood samples will be taken at baseline and 4 weeks to measure systemic markers of inflammation. |
| Change in plasma insulin levels over a 2-hour oral glucose tolerance test | 4 weeks | Insulin following 4 weeks of treatment with salsalate (4 g/day) or placebo. A 2-hour oral glucose tolerance test will be performed at baseline and 4 weeks to measure changes in plasma insulin levels. |
| Change in plasma fasting free fatty acid levels | 4 weeks | Fasting free fatty acids (FFA) following 4 weeks of treatment with salsalate (4 g/day) or placebo. Fasting blood samples will be taken at baseline and 4 weeks to measure changes in plasma fasting FFA. |
| Change in plasma glucose levels over a 2-hour oral glucose tolerance test | 4 weeks | Glucose following 4 weeks of treatment with salsalate (4 g/day) or placebo. A 2-hour oral glucose tolerance test will be performed at baseline and 4 weeks to measure changes in plasma glucose levels. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in ectopic fat | 4 weeks | Changes in ectopic fat following 4 weeks of treatment with salsalate (4 g/day) or placebo. A 3-Tesla whole abdominal MRI scan will be performed at baseline and 4 weeks to measure any potential changes in ectopic fat. |
| Change in diet | 4 weeks | Changes in diet following 4 weeks of treatment with salsalate (4 g/day) or placebo. A 24-hour diet recall will be performed at baseline and 4 weeks to measure any potential changes in diet. |
| Change in physical activity | 4 weeks | Changes in physical activity following 4 weeks of treatment with salsalate (4 g/day) or placebo. A Godin-Shephard Leisure-Time Physical Activity questionnaire will be performed at baseline and 4 weeks to measure any potential changes in physical activity. |
| Change in body composition | 4 weeks | Changes in body composition following 4 weeks of treatment with salsalate (4 g/day) or placebo. A DEXA scan will be performed at baseline and 4 weeks to measure any potential changes in body composition (body fat and lean tissue mass). |
Countries
United States
Outcome results
None listed